Enanta starts mid-stage trial of EDP-938 for RSV infection

Oct. 03, 2022 10:57 AM ETEnanta Pharmaceuticals, Inc. (ENTA)By: Ravikash, SA News Editor

Modern Medical Research Laboratory: Portrait of Latin and Black Young Scientists Using Microscope, Digital Tablet, Doing Sample Analysis, Talking. Diverse Team of Specialists work in Advanced Lab

gorodenkoff/iStock via Getty Images

  • Enanta Pharmaceuticals (NASDAQ:ENTA) said it started a phase 2b trial of EDP-938 to treat adults with acute respiratory syncytial virus (RSV) infection who are at high risk of complications, including elderly and/or those with congestive heart failure, chronic obstructive pulmonary disease (COPD) or asthma.
  • In the study 180 patients will be treated with 800 mg of EDP-938 or placebo for five days and evaluated for 28 days thereafter.
  • "In previous clinical studies, EDP-938 significantly improved the percentage of people with undetectable RSV RNA at the end of treatment, consistent with inhibiting viral replication," said President and CEO Jay Luly.

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.